We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

83 hedge funds and large institutions have $34.1M invested in Cardiff Oncology in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

439% more call options, than puts

Call options by funds: $2.19M | Put options by funds: $406K

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

17% more capital invested

Capital invested by funds: $29.1M → $34.1M (+$5.02M)

1.85% less ownership

Funds ownership: 29.26% → 27.41% (-1.8%)

8% less funds holding

Funds holding: 90 → 83 (-7)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

Holders
83
Holders Change
-7
Holders Change %
-7.78%
% of All Funds
1.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
27
Reduced
23
Closed
15
Calls
$2.19M
Puts
$406K
Net Calls
+$1.78M
Net Calls Change
+$156K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$1.05M
2
N
Nuveen
North Carolina
+$672K
3
Northern Trust
Northern Trust
Illinois
+$499K
4
GCP
GSA Capital Partners
United Kingdom
+$358K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$293K

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.23M
2
Marshall Wace
Marshall Wace
United Kingdom
-$368K
3
UOC
UBS O'Connor
Illinois
-$333K
4
Millennium Management
Millennium Management
New York
-$205K
5
JF
Jump Financial
Illinois
-$191K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$46.5K +$1.62K +685 +4%
FWS
52
FinDec Wealth Services
California
$42.7K – – –
HighTower Advisors
53
HighTower Advisors
Illinois
$41K -$1.66K -702 -4%
DWM
54
Denver Wealth Management
Colorado
$40.7K – – –
GIA
55
Gladstone Institutional Advisory
Florida
$40K – – –
TFS
56
Thoroughbred Financial Services
Tennessee
$36K -$91.5K -38,731 -74%
PI
57
PFG Investments
New York
$33.4K – – –
Simplex Trading
58
Simplex Trading
Illinois
$33K -$28.5K -12,074 -49%
AllianceBernstein
59
AllianceBernstein
Tennessee
$27.7K – – –
TIM
60
Tortoise Investment Management
New York
$26.7K – – –
SNB
61
Security National Bank
Nebraska
$26.1K – – –
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$14K -$37.1K -15,703 -75%
TRCT
63
Tower Research Capital (TRC)
New York
$12.5K -$66.2K -28,021 -86%
AIP
64
Ameritas Investment Partners
Nebraska
$10.2K – – –
Legal & General Group
65
Legal & General Group
United Kingdom
$10.2K – – –
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
$9.61K -$93.1K -39,400 -92%
US Bancorp
67
US Bancorp
Minnesota
$8.3K +$7.09K +3,000 +2,752%
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$7.58K – – –
Fidelity Investments
69
Fidelity Investments
Massachusetts
$4.07K +$2.89K +1,225 +408%
PNC Financial Services Group
70
PNC Financial Services Group
Pennsylvania
$4.06K – – –
AB
71
Amalgamated Bank
New York
$4K – – –
Osaic Holdings
72
Osaic Holdings
Arizona
$3.74K – – –
MWA
73
Moser Wealth Advisors
Washington
$2.15K – – –
CA
74
Clearstead Advisors
Ohio
$1.87K – – –
VWWMG
75
Vermillion & White Wealth Management Group
Pennsylvania
$1.33K – – –
1 2
3
4

CRDF Hedge Fund Activity: Q3 2024 in Review

83 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2024, worth a combined $34.1M — up 17% from $29.1M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CRDF and 8 opened new positions — a net loss of 7 holders — while 23 trimmed existing stakes and 27 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.05M. The largest seller was Assenagon Asset Management, cutting an estimated $2.23M.

  • 83 institutional investors held Cardiff Oncology (CRDF) as of Q3 2024, down from 90 in Q2 2024.
  • Funds reported $34.1M of Cardiff Oncology stock for Q3 2024, up 17% quarter-over-quarter.
  • 8 funds opened new Cardiff Oncology positions in Q3 2024 and 15 closed out, a net change of -7 holders.
  • The largest Cardiff Oncology buyer in Q3 2024 was Renaissance Technologies, an estimated $1.05M added.
  • The largest Cardiff Oncology seller in Q3 2024 was Assenagon Asset Management, an estimated $2.23M sold.

Based on aggregated 13F filings for Q3 2024.